Patent Grant
7666803
The present invention relates to a reinforced absorbable multilayered fabric that is useful in medical devices.
It is generally known to use multilayered fabrics in connection with medical procedures. For example, multilayered fabrics are used as all purpose pads, wound dressings, surgical meshes, including hernia repair meshes, adhesion prevention meshes and tissue reinforcement meshes, defect closure devices, and hemostats.
U.S. Pat. No. 5,593,441 to Lichtenstein et al describes a composite prosthesis preferably having a sheet of polypropylene mesh that allows tissue in-growth, such as Marlex® mesh. This reference discloses that other surgical materials that are suitable for tissue reinforcement and defect closure may be utilized, including absorbable meshes such as a polyglactin 910 (Vicryl®) mesh. The composite prosthesis of Lichtenstein et al also has an adhesion barrier, preferably a sheet of silicone elastomer. This reference generally suggests that that an oxidized regenerated cellulose such as Interceed® (TC7) absorbable adhesion barrier (commercially available from Ethicon, Inc., in Somerville, N.J.) may be used as the adhesion barrier to produce a composite prosthesis having short term effectiveness. The composite prosthesis of Lichtenstein et al is described for use in reinforcing and repairing a weakened muscular wall while limiting the incidence of postoperative adhesions.
U.S. Pat. No. 5,686,090 to Schilder et al describes the use of a fleece in combination with a nonabsorbable or absorbable film to prevent mis-growths to adjacent tissue and to reduce adhesions. Schilder et al generally discloses that polypropylene, polyester, polyglactin, polydioxanone or poliglecaprone 25 may be used as the fleece material or the film material. The term “fleece” as used in this reference is described by its porosity, which is described as being in the range between 100 and 1000 1/(m2s) gas flow, measured with an inlet pressure of 200 Pa, a test surface of 50 cm2 and a test thickness of 1 mm. The composite of Schilder et al is generally described as being a multilayered implant.
Additionally, multilayered fabrics are useful for tissue engineering and orthopedic applications. The recent emergence of tissue engineering offers numerous approaches to repair and regenerate damaged/diseased tissue. Tissue engineering strategies have explored the use of biomaterials that ultimately can restore or improve tissue function. The use of colonizable and remodelable scaffolding materials has been studied extensively as tissue templates, conduits, barriers and reservoirs. In particular, synthetic and natural materials in the form of foams, sponges, gels, hydrogels, textiles, and nonwovens have been used in vitro and in vivo to reconstruct/regenerate biological tissue, as well as deliver chemotactic agents for inducing tissue growth. The different forms of scaffolds may be laminated to form a multilayered tissue engineering scaffold.
However, the prior art fails to describe or suggest a reinforced absorbable multilayered fabric having a first absorbable nonwoven fabric reinforced by a second absorbable woven or knitted fabric.
As used herein, the term “nonwoven fabric” includes, but is not limited to, bonded fabrics, formed fabrics, or engineered fabrics, that are manufactured by processes other than spinning, weaving or knitting. More specifically, the term “nonwoven fabric” refers to a porous, textile-like material, usually in flat sheet form, composed primarily or entirely of staple fibers assembled in a web, sheet or batt. The structure of the nonwoven fabric is based on the arrangement of, for example, staple fibers that are typically arranged more or less randomly. The tensile, stress-strain and tactile properties of the nonwoven fabric ordinarily stem from fiber to fiber friction created by entanglement and reinforcement of, for example, staple fibers, and/or from adhesive, chemical or physical bonding. Notwithstanding, the raw materials used to manufacture the nonwoven fabric may be yarns, scrims, netting, or filaments made by processes that include spinning, weaving or knitting.
The present invention is directed to a reinforced absorbable multilayered fabric comprising a first absorbable nonwoven fabric reinforced by a second absorbable woven or knitted fabric. More particularly, the first absorbable nonwoven fabric comprises fibers comprising aliphatic polyester polymers, copolymers, or blends thereof; while the second absorbable woven or knitted fabric comprises oxidized regenerated cellulose fibers.
The reinforced absorbable multilayered fabric generally comprises a nonwoven fabric and a reinforcement fabric. The reinforcement fabric provides a backing to which the nonwoven fabric may be attached, either directly or indirectly.
The nonwoven fabric functions as the first absorbable nonwoven fabric of the reinforced absorbable multilayered fabric described herein. The first absorbable nonwoven fabric is comprised of fibers comprising aliphatic polyester polymers, copolymers, or blends thereof. The aliphatic polyesters are typically synthesized in a ring opening polymerization of monomers including, but not limited to, lactic acid, lactide (including L-, D-, meso and D, L mixtures), glycolic acid, glycolide, ε-caprolactone, p-dioxanone (1,4-dioxan-2-one), and trimethylene carbonate (1,3-dioxan-2-one).
Preferably, the first absorbable nonwoven fabric comprises a copolymer of glycolide and lactide, in an amount ranging from about 70 to 95% by molar basis of glycolide and the remainder lactide.
In an alternative embodiment, the first absorbable nonwoven fabric comprises fibers comprised of aliphatic polyester polymers, copolymers, or blends thereof, in combination with oxidized polysaccharide fibers.
Preferably, the nonwoven fabric is made by processes other than spinning, weaving or knitting. For example, the nonwoven fabric may be prepared from yarn, scrims, netting or filaments that have been made by processes that include spinning, weaving or knitting. The yarn, scrims, netting and/or filaments are crimped to enhance entanglement with each other and attachment to the second absorbable woven or knitted fabric. Such crimped yarn, scrims, netting and/or filaments may then be cut into staple that is long enough to entangle. The staple may be between about 0.1 and 3.0 inches long, preferably between about 0.75 and 2.5 inches, and most preferably between about 1.5 and 2.0 inches. The staple may be carded to create a nonwoven batt, which may be then needlepunched or calendared into the first absorbable nonwoven fabric. Additionally, the staple may be kinked or piled.
Other methods known for the production of nonwoven fabrics may be utilized and include such processes as air laying, wet forming and stitch bonding. Such procedures are generally discussed in the Encyclopedia of Polymer Science and Engineering, Vol. 10, pp. 204-253 (1987) and Introduction to Nonwovens by Albin Turbank (Tappi Press, Atlanta Ga. 1999), both incorporated herein in their entirety by reference.
The thickness of the nonwoven fabric may range from about 0.25 to 2 mm. The basis weight of the nonwoven fabric ranges from about 0.01 to 0.2 g/in2; preferably from about 0.03 to 0.1 g/in2; and most preferably from about 0.04 to 0.08 g/in2. The weight percent of first absorbable nonwoven fabric may range from about 10 to 80 percent, based upon the total weight of the reinforced absorbable multilayered fabric.
The second absorbable woven or knitted fabric functions as the reinforcement fabric and comprises oxidized polysaccharides, in particular oxidized cellulose and the neutralized derivatives thereof. For example, the cellulose may be carboxylic-oxidized or aldehyde-oxidized cellulose. More preferably, oxidized regenerated polysaccharides including, but without limitation, oxidized regenerated cellulose may be used to prepare the second absorbable woven or knitted fabric. Regenerated cellulose is preferred due to its higher degree of uniformity versus cellulose that has not been regenerated. Regenerated cellulose and a detailed description of how to make oxidized regenerated cellulose are set forth in U.S. Pat. Nos. 3,364,200, 5,180,398 and 4,626,253, the contents each of which is hereby incorporated by reference as if set forth in its entirety.
Examples of fabrics that may be utilized as the reinforcement fabric include, but are not limited to, Interceed® absorbable adhesion barrier, Surgicel® absorbable hemostat, Surgicel Nu-Knit® absorbable hemostat and Surgicel® Fibrillar absorbable hemostat (each available from Johnson & Johnson Wound Management Worldwide or Gynecare Worldwide, each a division of Ethicon, Inc., Somerville, N.J.).
The reinforcement fabric utilized in the present invention may be woven or knitted, provided that the fabric possesses the physical properties necessary for use in contemplated applications. Such fabrics, for example, are described in U.S. Pat. Nos. 4,626,253, 5,002,551 and 5,007,916, the contents of which are hereby incorporated by reference herein as if set forth in its entirety. In preferred embodiments, the reinforcement fabric is a warp knitted tricot fabric constructed of bright rayon yarn that is subsequently oxidized to include carboxyl or aldehyde moieties in amounts effective to provide the fabrics with biodegradability.
In an alternative embodiment, the second absorbable woven or knitted fabric comprises oxidized polysaccharide fibers in combination with fibers comprised of aliphatic polyester polymers, copolymers, or blends thereof.
The second absorbable woven or knitted fabric preferably comprises oxidized regenerated cellulose and may have a basis weight ranging from about 0.001 to 0.2 g/in2, preferably in the range of about 0.01 to 0.1 g/in2, and most preferably in the range of about 0.04 to 0.07 g/in2.
The first absorbable nonwoven fabric is attached to the second absorbable woven or knitted fabric, either directly or indirectly. For example, the nonwoven fabric may be incorporated into the second absorbable woven or knitted fabric via needlepunching, calendaring, embossing or hydroentanglement, or chemical or thermal bonding. The staple of the first absorbable nonwoven fabric may be entangled with each other and imbedded in the second absorbable woven or knitted fabric. More particularly, for methods other than chemical or thermal bonding, the first absorbable nonwoven fabric may be attached to the second absorbable woven or knitted fabric such that at least about 1% of the staple of the first absorbable nonwoven fabric are exposed on the other side of the second absorbable woven or knitted fabric, preferably about 10-20% and preferably no greater than about 50%. This ensures that the first absorbable nonwoven fabric and the second absorbable woven or knitted fabric remain joined and do not delaminate under normal handling conditions. The reinforced absorbable multilayered fabric is uniform such that substantially none of the second absorbable woven or knitted fabric is visibly devoid of coverage by the first absorbable nonwoven fabric.
One method of making the multilayered fabric described herein is by the following process. Absorbable polymer fibers, having a denier per fiber of about 1 to 4, may be consolidated to about 80 to 120, denier multifilament yarn and then to about 800 to 1200 denier yarns, thermally crimped and then cut to a staple having a length between about 0.75 and 1.5 inch. The staple may be fed into a multiroller dry lay carding machine one or more times and carded into a uniform nonwoven batt, while humidity is controlled between about 40-60% at a room temperature of 60 to 75° F. For example, the uniform nonwoven batt may be made using a single cylinder roller-top card, having a main cylinder covered by alternate rollers and stripper rolls, where the batt is doffed from the surface of the cylinder by a doffer roller and deposited on a collector roll. The batt may be further processed via needlepunching or any other means such as calendaring. Thereafter, the first absorbable nonwoven fabric may be attached to the second absorbable woven or knitted fabric by various techniques such as needlepunching. The reinforced absorbable multilayered fabric may then be scoured by washing in an appropriate solvent and dried under mild conditions for approximately 30 minutes.
It is desirable to control process parameters such as staple length, opening of the staple, staple feed rate, and relative humidity. For example, the consolidated yarns may have from about 5 to 50 crimps per inch, and preferably from about 10 to 30 crimps per inch. Efficient cutting of the crimped yarns is desirable, as any long and incompletely cut staple tends to stick on the carding machine and cause pilling. A preferred range of the staple length is from about 0.75 to 2.5 inches, and more preferably from about 1.5 to 2.0 inches.
To optimize uniformity and minimize the build-up of static electricity, the relative humidity may be controlled during batt processing, preferably during carding to form the uniform nonwoven batt. Preferably, the nonwoven batt is processed using a dry lay carding process at a relative humidity of at least about 40% at a room temperature of about 60 to 75° F. More preferably, the nonwoven batt is processed at a relative humidity of from about 50% to 60%.
The multilayered fabric is scoured using solvents suitable to dissolve any spin finish. Solvents include, but are not limited to, isopropyl alcohol, hexane, ethyl acetate, and methylene chloride. The multilayered fabric is then dried under conditions to provide sufficient drying while minimizing shrinkage.
The reinforced absorbable multilayered fabric may have an average thickness of between about 0.75 and 3.0 mm, preferably between about 1.00 and 2.5 mm, and most preferably between about 1.2 and 2.0 mm. The basis weight of the reinforced absorbable multilayered fabric is between about 0.05 and 0.25 g/in2, preferably between about 0.08 and 0.2 g/in2, and most preferably between about 0.1 and 0.18 g/in2. The reinforced absorbable multilayered fabric is uniform such that there is no more than about 10% variation (relative standard deviation of the mean) in the basis weight or thickness across each square inch.
Additionally, the nonwoven fabric may comprise biologically active agents, such as hemostatic agents. Hemostatic agents that may be used include, without limitation, procoagulant enzymes, proteins and peptides, either naturally occurring, recombinant, or synthetic. More specifically, prothrombin, thrombin, fibrinogen, fibrin, fibronectin, Factor X/Xa, Factor VII/VIIa, Factor IX/IXa, Factor XI/XIa, Factor XII/XIIa, tissue factor, von Willebrand Factor, collagen, elastin, gelatin, synthetic peptides having hemostatic activity, derivatives of the above and any combination thereof, may be utilized. Preferred hemostatic agents are thrombin, fibrinogen and fibrin.
Additionally, the nonwoven fabric may comprise pharmacologically and biologically active agents, including but not limited to, wound healing agents, antibacterial agents, antimicrobial agents, growth factors, analgesic and anesthetic agents. When used as a tissue scaffold, the reinforced absorbable multilayer fabric may be seeded or cultured with appropriate cell types prior to implantation for the targeted tissue.
Poly (glycolide-co-lactide) (PGL, 90/10 mol/mol) was melt-spun into fiber. A multi-filament yarn was consolidated, crimped and cut into staple having a length of 1.75 inches. The staple was carded to create a nonwoven batt and then compacted to a thickness of about 1.25 mm and a density of about 98.1 mg/cc. The nonwoven fabric was then needlepunched into a knitted carboxylic-oxidized regenerated cellulose (ORC) fabric, available from Ethicon, Inc., under the tradename Interceed®, to secure the nonwoven fabric to the ORC fabric. The final multilayered fabric comprised about 60 weight percent of the nonwoven fabric.
Poly (glycolide-co-lactide) (PGL, 90/10 mol/mol) was melt-spun into fiber. A multi-filament yarn was consolidated, crimped and cut into staple having a length of 1.75 inches. The staple was carded to create a nonwoven batt and then compacted to a thickness of about 1.22 mm and a density of about 103.4 mg/cc. The nonwoven fabric was then needlepunched into a knitted carboxylic-oxidized regenerated cellulose fabric (ORC), available from Ethicon, Inc., under the tradename Surgicel NuKnit®, to secure the nonwoven fabric to the ORC fabric. The final multilayered fabric comprised about 25 weight percent of the nonwoven fabric.
Poly (glycolide-co-lactide) (PGL, 90/10 mol/mol) was melt-spun into fiber. A multi-filament yarn was consolidated, crimped and cut into staple having a length of 1.75 inches. The staple was carded to create a nonwoven batt and then compacted a felt having a thickness of about 1.1 mm and a density of about 102.8 mg/cc. The nonwoven fabric was then needlepunched into a knitted carboxylic-oxidized regenerated cellulose fabric (ORC), available from Ethicon, Inc., under the tradename Surgicel®, to secure the nonwoven fabric to the ORC fabric. The final multilayered fabric comprised about 60 weight percent of the nonwoven fabric.
Poly (glycolide-co-lactide) (PGL, 90/10 mol/mol) was melt-spun into fiber. A 80 denier multifilament yarn was consolidated into a 800 denier consolidated yarn. The consolidated yarn was crimped at approximately 110 degree C. The crimped yarn was cut into staple having a length of about 1.25″ in length. 20 g of the crimped staple was accurately weighed and laid out uniformly on the feed conveyor belt of a multi-roller carding machine. The environmental conditions (temp: 70 deg F./55% RH) were controlled. The staple was then carded to create a nonwoven batt. The batt was removed from the pick-up roller and cut into 4 equal parts. These were re-fed into the carder perpendicular to the collection direction. After this second pass the batt was weighed (19.8 g: 99% fabric yield) and then compacted into a felt. The compact felt was precisely laid onto an ORC fabric and firmly attached via 2 passes in the needlepunching equipment. The multilayered fabric was trimmed and scoured in 3 discrete isopropyl alcohol baths to remove spin finish and any machine oils. The scoured multilayered fabric was dried in an oven at 70 degree C. for 30 minutes, cooled and weighed.
The “thickness” of the multilayered fabric was measured as described herein. The measurement tools were:
The multilayered fabric was placed on a platen surface that is a smooth and machined surface. The two metal plates were placed on top of each other on the multilayered fabric and gently pressed at their corners to make sure the multilayered fabric is flat. The gauge foot was placed onto the top of the metal plates and was then re-lifted and re-placed, at which time a reading was made.
12-1″×1″ pieces were die-cut from the scoured multilayered fabric and accurately weighed. The thickness of each 1″×1″ piece was measured 4-5 times in different areas of the metal plate in order to obtain a reliable average. The weight and thickness of each piece is shown in Table 1. The values indicate that the coverage of both layers is similar in all directions.
80 denier polyglactin 910 consolidated yarn was crimped and cut into 1.75 inch staple. Room temperature was maintained between 69-70° F. and the relative humidity was controlled by a room humidifier and varied from 36-60%. Crimped staple was carded into a batt approximately 32″×8″. The percent of staple incorporated into the batt after two passes through the carding machine, i.e., the yield, increased with increasing humidity, and the quality of the batt improved with yield.
80 denier polyglactin 910 consolidated yarn was crimped and cut into 1.25″, 1.5″ and 1.75″ long staple. Room temperature was maintained between 69-71° F. and the relative humidity was controlled at ˜55% by a room humidifier. Crimped staple was carded into a batt approximately 32″×8″.
In the case of a rotator cuff problem, the surgeon first looks at the extent of an injury using an arthroscope. Then, under general anesthesia, the patient undergoes open surgery to repair the tear.
After the anesthetic has been administered and the shoulder has been prepared, a cosmetic incision is made over the top front corner of the shoulder. This incision allows access to the seam between the front and middle parts of the deltoid muscle. Splitting this seam allows access to the rotator cuff without detaching or damaging the important deltoid muscle, which is responsible for a significant portion of the shoulder's power. All scar tissue is removed from the space beneath the deltoid and the acromion (part of the shoulder blade to which the deltoid attaches). Thickened bursa and the rough edges of the rotator cuff and humerus (upper arm bone) are also smoothed to make sure that they pass smoothly beneath the acromion and deltoid.
The edges of the cuff tendons are identified and the quality and quantity of the cuff tissue is determined. The goal of the repair is to reattach good quality tendon to the location on the arm bone from which it was torn. A groove or trough is fashioned in the normal attachment site for the cuff. To support the tendon and aid in healing, the surgeon sutures a patch of reinforced absorbable multilayered fabric into place over it. Sutures (lengths of surgical thread) draw the edge of the tendon securely into the groove to which it is to heal.
The surgeon then completes the surgery by closing the deltoid muscle and the skin incision. Over time, the body creates new tissue in the area that matches surrounding tissue. The body also absorbs the implanted patch in two to four months.
First, the surgeon examines the knee through an arthroscope—a small device that allows the doctor to see into your knee joint. If a lesion is detected, a surgical procedure is performed.
After the anesthetic has been administered and the knee has been prepared, a cosmetic incision is made through the skin over the top front corner of the patella. First, the damaged cartilage is removed. The reinforced absorbable multilayered fabric is then implanted into the lesion. The fabric may be attached to the lesion site with sutures, tacks, or any of a number of biocompatible glues.
The surgeon then completes the surgery by closing the skin incision. Cartilage cells migrate into and multiply in the implanted fabric, and the cell/fabric implant intergrates with surrounding cartilage. With time, the cells will mature and fill-in the lesion with hyaline cartilage.
While the examples demonstrate certain embodiments of the invention, they are not to be interpreted as limiting the scope of the invention, but rather as contributing to a complete description of the invention. All reinforcement fabrics described in the examples below are the nonsterile materials of the corresponding commercial products referred by their tradenames.
This application claims priority from U.S. Provisional Application Ser. No. 60/620,624, filed on 20 Oct. 2004.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2517772 | Doub et al. | Aug 1950 | A |
| 2773000 | Masci | Dec 1956 | A |
| 2914444 | Smith | Nov 1959 | A |
| 3328529 | Anderson | Jun 1967 | A |
| 3364200 | Aston et al. | Jan 1968 | A |
| 3868955 | Siragusa et al. | Mar 1975 | A |
| 3875937 | Schmitt et al. | Apr 1975 | A |
| 4214582 | Patel | Jul 1980 | A |
| 4289824 | Smith | Sep 1981 | A |
| 4407787 | Stemberger | Oct 1983 | A |
| 4534349 | Barrows | Aug 1985 | A |
| 4543410 | Cruz, Jr. | Sep 1985 | A |
| 4600574 | Lindner | Jul 1986 | A |
| 4626253 | Broadnax | Dec 1986 | A |
| 4752466 | Saferstein et al. | Jun 1988 | A |
| 4840626 | Linsky | Jun 1989 | A |
| 4882162 | Ikada et al. | Nov 1989 | A |
| 4948540 | Nigam | Aug 1990 | A |
| 5002551 | Linsky et al. | Mar 1991 | A |
| 5007916 | Linsky et al. | Apr 1991 | A |
| 5026589 | Schechtman | Jun 1991 | A |
| 5134229 | Saferstein et al. | Jul 1992 | A |
| 5180398 | Boardman et al. | Jan 1993 | A |
| 5393594 | Koyfman et al. | Feb 1995 | A |
| 5409703 | Hall | Apr 1995 | A |
| 5593441 | Lichtenstein et al. | Jan 1997 | A |
| 5643596 | Pruss et al. | Jul 1997 | A |
| 5645849 | Pruss et al. | Jul 1997 | A |
| 5683794 | Wadsworth et al. | Nov 1997 | A |
| 5686090 | Schilder et al. | Nov 1997 | A |
| 5795584 | Totakura et al. | Aug 1998 | A |
| 5821343 | Keogh | Oct 1998 | A |
| 5843057 | McCormack | Dec 1998 | A |
| 5866165 | Liu et al. | Feb 1999 | A |
| 5914118 | Yamamura et al. | Jun 1999 | A |
| 5925552 | Keogh et al. | Jul 1999 | A |
| 5945319 | Keogh | Aug 1999 | A |
| 6017741 | Keogh | Jan 2000 | A |
| 6165217 | Hayes | Dec 2000 | A |
| 6214808 | Soe et al. | Apr 2001 | B1 |
| 6261679 | Chen et al. | Jul 2001 | B1 |
| 6306424 | Vyakamam et al. | Oct 2001 | B1 |
| 6333029 | Vyakamam et al. | Dec 2001 | B1 |
| 6365149 | Vyakamam et al. | Apr 2002 | B2 |
| 6500777 | Wiseman et al. | Dec 2002 | B1 |
| 6649162 | Wolfgang et al. | Nov 2003 | B1 |
| 6762336 | MacPhee et al. | Jul 2004 | B1 |
| 20010025154 | Rapp | Sep 2001 | A1 |
| 20020012693 | Diegelmann et al. | Jan 2002 | A1 |
| 20020120348 | Melican et al. | Aug 2002 | A1 |
| 20020173213 | Chu et al. | Nov 2002 | A1 |
| 20030073663 | Wisemann et al. | Apr 2003 | A1 |
| 20030171052 | Bansal et al. | Sep 2003 | A1 |
| 20040001879 | Guo et al. | Jan 2004 | A1 |
| 20040005350 | Looney et al. | Jan 2004 | A1 |
| 20040078077 | Binette et al. | Apr 2004 | A1 |
| 20040101546 | Gorman et al. | May 2004 | A1 |
| 20040101547 | Pendharkar | May 2004 | A1 |
| 20040101548 | Pendharkar | May 2004 | A1 |
| 20040120993 | Zhang et al. | Jun 2004 | A1 |
| 20040193088 | Looney et al. | Sep 2004 | A1 |
| 20040243043 | McCarthy et al. | Dec 2004 | A1 |
| 20050123588 | Zhu et al. | Jun 2005 | A1 |
| Number | Date | Country |
|---|---|---|
| 217243 | Dec 1982 | CS |
| 235108 | May 1985 | CS |
| 238016 | Nov 1985 | CS |
| 0109197 | May 1984 | EP |
| 0177064 | Apr 1986 | EP |
| 0216378 | Apr 1987 | EP |
| 0361842 | Apr 1990 | EP |
| 0372969 | Jun 1990 | EP |
| 0468114 | Jan 1992 | EP |
| 0338829 | Aug 1993 | EP |
| 0610731 | Aug 1994 | EP |
| 0636378 | Feb 1995 | EP |
| 0647734 | Apr 1995 | EP |
| 0815879 | Jan 1998 | EP |
| 0878179 | Nov 1998 | EP |
| 1172115 | Jan 2002 | EP |
| 1378255 | Jan 2004 | EP |
| 1400624 | Mar 2004 | EP |
| 1424086 | Jun 2004 | EP |
| 1424087 | Jun 2004 | EP |
| 1430911 | Jun 2004 | EP |
| 1462122 | Sep 2004 | EP |
| 1574229 | Sep 2005 | EP |
| 0942305 | Nov 1963 | GB |
| 983073 | Feb 1965 | GB |
| 2314840 | Jan 1998 | GB |
| 2314842 | Jan 1998 | GB |
| 2344519 | Jun 2000 | GB |
| 159332 | May 1987 | IN |
| 6087225 | May 1985 | JP |
| 2146264 | Mar 2000 | RU |
| 2235539 | Sep 2004 | RU |
| WO 9108726 | Jun 1991 | WO |
| WO 96016643 | Jun 1996 | WO |
| WO 9640033 | Dec 1996 | WO |
| WO 9800180 | Jan 1998 | WO |
| WO 98000446 | Jan 1998 | WO |
| WO 9833479 | Aug 1998 | WO |
| WO 9901166 | Jan 1999 | WO |
| WO 0001166 | Jan 2000 | WO |
| WO 0122059 | Mar 2001 | WO |
| WO 0123653 | Apr 2001 | WO |
| WO 0202155 | Jan 2002 | WO |
| WO 0222059 | Mar 2002 | WO |
| WO 02058750 | Aug 2002 | WO |
| WO 03020191 | Mar 2003 | WO |
| WO 2006044882 | Apr 2006 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20060084338 A1 | Apr 2006 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60620624 | Oct 2004 | US |
